InvestorsObserver
Sign Up Login

SYRS Syros Pharmaceuticals Inc.

$2.72 $-0.07 (-2.51%)
15 Minute Delayed Price Enable Real-Time Price
Add to Watchlist Compare
Overall

SYRS Stock Analysis Overview

What this means: InvestorsObserver gives Syros Pharmaceuticals Inc. (SYRS) an overall rank of 28, which is below average. Syros Pharmaceuticals Inc. is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 28 means that 72% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

View Sample Report
Fundamental PREMIUM

SYRS Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

Short-Term Technical PREMIUM

SYRS Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

Long-Term Technical PREMIUM

SYRS Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

Analyst Ranking PREMIUM

SYRS Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

Valuation PREMIUM

SYRS Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

Stock Sentiment PREMIUM

SYRS Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

SYRS Stock Analysis Overview

What this means: InvestorsObserver gives Syros Pharmaceuticals Inc. (SYRS) an overall rank of 28, which is below average. Syros Pharmaceuticals Inc. is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 28 means that 72% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full SYRS report

SYRS Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

SYRS Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

SYRS Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

SYRS Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

SYRS Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

SYRS Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

Syros Pharmaceuticals Inc. (SYRS) Analyst Forecast

SYRS Price, Volume, Earnings, and Dividend Date

  • Last Price $2.72
  • Previous Close $2.79
  • Change $-0.07
  • Open $2.84
  • Volume 58,815
  • Avg. Volume (100-day) 123,984
  • Market Cap 55,217,140
  • Days Range 2.68 - 2.84
  • 52-week Range 2.67 - 14.3
  • Dividend Yield —
  • Ex. Dividend Date —
  • P-E 3.1
  • EPS —
  • Earnings Date 05/15/23
  • Sector Healthcare
  • Industry Biotechnology
  • Avg. Analyst Rec. Premium
  • Beta 1.300
  • PEG Ratio —

Syros Pharmaceuticals Inc. (SYRS) Company Description

Syros Pharmaceuticals Inc is a biopharmaceutical company engaged in a non-coding regulatory region of the genome controlling the activation and repression of genes. It is mainly involved in the segments of pharmaceutical, biotechnology, and other related markets that address gene control and cancer. The Company operates only in the United States.

Syros Pharmaceuticals Inc. (SYRS) Stock Chart

View Interactive SYRS chart

My Watchlists

Top Stocks in Biotechnology